Scarica l'app Stockscreener
23.23
4.97%
1.10
Dopo l'orario di chiusura:
22.88
-0.35
-1.51%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Aberdeen Group Boosts Stake in Sarepta Therapeutics - National Today
Aberdeen Group plc Increases Stake in Sarepta Therapeutics, Inc. $SRPT - marketbeat.com
Why is Sarepta Therapeutics (SRPT) up 24.2% since last earnings report? - MSN
The Precedent: Federal Circuit Upholds Gene Therapy Host Cell Claims Under 35 U.S.C. § 101 in Regenxbio Inc., Et Al. v. Sarepta Therapeutics, Inc., Et Al. - JD Supra
SG Americas Securities Trims Sarepta Therapeutics Stake - National Today
SG Americas Securities LLC Lowers Holdings in Sarepta Therapeutics, Inc. $SRPT - marketbeat.com
Sarepta gets New Zealand approval for Huntington’s disease trial - Investing.com
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Wealth Enhancement Advisory Services LLC Acquires 62,981 Shares of Sarepta Therapeutics, Inc. $SRPT - marketbeat.com
Sarepta Therapeutics, Inc. (SRPT) Stock forecasts - Yahoo Finance UK
SRPT Stock Price, Quote & Chart | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - finance.yahoo.com
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - finance.yahoo.com
Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Sarepta plans FDA filings seeking full approval for two DMD therapies - msn.com
Trend Review: How volatile is Sarepta Therapeutics Inc stock2026 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn
Sarepta to soon submit SNDAs for traditional approval for Duchenne treatments - msn.com
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance - Yahoo Finance
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector - MSN
Mirador Capital Partners Invests $3M in Sarepta Therapeutics - National Today
Mirador Capital Partners LP Invests $3.01 Million in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Massachusetts Biotech Co. Finds High-Potential Muscle Treatment Breakthrough - Streetwise Reports
Biotech Price Target Raised on Strong FSHD & DM1 siRNA Data - Streetwise Reports
Sarepta (SRPT) skyrockets 35% on Morgan Stanley PT hike, stellar trial results - msn.com
Gene Therapy And US Patent Eligibility Update: REGENXBIO, Inc. v. Sarepta Therapeutics, Inc. - MarketScreener
Sarepta Therapeutics Inc (SRPT) Stock Price & 30 Year Financial Data - GuruFocus
Why has Sarepta Therapeutics (SRPT) risen by 24.2% following its most recent earnings announcement? - Bitget
Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday? - Benzinga
Vanguard realigns reporting; reports 0 shares of Sarepta (SRPT) - Stock Titan
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
(SRPT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Tranche Update on Sarepta Therapeutics, Inc.'s Equity Buyback Plan announced on February 26, 2025. - marketscreener.com
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 8%Here's What Happened - MarketBeat
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline - Streetwise Reports
SRPT Stock Surges on Promising Early Results From siRNA Programs - The Globe and Mail
Sarepta TherapeuticsIt's Too Early To Get Excited About siRNA Data (NASDAQ:SRPT) - Seeking Alpha
SRPT: Citigroup Raises Price Target Amid Maintained 'Sell' Ratin - GuruFocus
Sarepta Therapeutics Is Maintained at Sell by Citigroup - Moomoo
Sarepta Therapeutics (NASDAQ:SRPT) Given New $13.00 Price Target at Citigroup - MarketBeat
Deutsche Bank Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Raises Target Price to $14 - Moomoo
Deutsche Bank Adjusts Price Target for Sarepta (SRPT) Amid Stock Rally - GuruFocus
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $5 to $35 - Moomoo
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Sarepta Therapeutics (SRPT) Retains 'Underperform' Rating by Nee - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Earns Underperform Rating from Needham & Company LLC - marketbeat.com
Which Is a Better Investment, Apellis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. Stock? - AAII.com
Early-stage data allows Sarepta to bounce back - The Pharma Letter
Deutsche Bank Raises Price Target on Sarepta Therapeutics to $14 From $12, Keeps Sell Rating - marketscreener.com
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise - BioSpace
Urban-gro, DraftKings, Sarepta Therapeutics, Destiny Tech100 and AMD: Why these 5 stocks are on investors' radars today - MSN
Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results Spark Share Price Rebound - Yahoo Finance
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):